Eli Lilly and Company — Third Quarter 2026 Earnings Summary

Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, a 39% increase driven primarily by sales of Mounjaro and Zepbound. The company raised its full-year 2026 revenue guidance to a range of $91.0 to $92.0 billion and adjusted its non-GAAP earnings per share guidance to $35.00 to $36.00. Regulatory milestones included FDA approvals for Mounjaro to reduce cardiovascular risk, the once-weekly insulin Onswik, and expanded indications for Inluriyo and Jaypirca. Business development activities in the quarter involved the acquisition of AtaiBeckley, with a subsequent acquisition of Merida Biosciences completed after the quarter ended.